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childhood malignancies. Early detection of cardiac dysfunction may identify a high-risk subset of survivors for early
intervention.
OBJECTIVES This study sought to determine the prevalence of cardiac dysfunction in adult survivors of childhood
malignancies.
METHODS Echocardiographic assessment included 3-dimensional (3D) left ventricular ejection fraction (LVEF), global
longitudinal and circumferential myocardial strain, and diastolic function, graded per American Society of Echocardiog-
raphy guidelines in 1,820 adult (median age 31 years; range: 18 to 65 years) survivors of childhood cancer (median time
from diagnosis 23 years; range: 10 to 48 years) exposed to anthracycline chemotherapy (n ¼ 1,050), chest-directed
radiotherapy (n ¼ 306), or both (n ¼ 464).
RESULTS Only 5.8% of survivors had abnormal 3D LVEFs (<50%). However, 32.1% of survivors with normal 3D LVEFs
had evidence of cardiac dysfunction by global longitudinal strain (28%), American Society of Echocardiography–graded
diastolic assessment (8.7%), or both. Abnormal global longitudinal strain was associated with chest-directed radio-
therapy at 1 to 19.9 Gy (rate ratio [RR]: 1.38; 95% conﬁdence interval [CI]: 1.14 to 1.66), 20 to 29.9 Gy (RR: 1.65; 95%
CI: 1.31 to 2.08), and >30 Gy (RR: 2.39; 95% CI: 1.79 to 3.18) and anthracycline dose > 300 mg/m2 (RR: 1.72; 95% CI: 1.31
to 2.26). Survivors with metabolic syndrome were twice as likely to have abnormal global longitudinal strain (RR: 1.94;
95% CI: 1.66 to 2.28) and abnormal diastolic function (RR: 1.68; 95% CI: 1.39 to 2.03) but not abnormal 3D LVEFs
(RR: 1.07; 95% CI: 0.74 to 1.53).
CONCLUSIONS Abnormal global longitudinal strain and diastolic function are more prevalent than reduced 3D LVEF
and are associated with treatment exposure. They may identify a subset of survivors at higher risk for poor clinical cardiac
outcomes who may beneﬁt from early medical intervention. (J Am Coll Cardiol 2015;65:2511–22) © 2015 by the American
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2512I n the modern era, more than 80% ofchildren and adolescents diagnosedwith malignancies will become long-
term cancer survivors (1,2). However, as
these patients age, the therapies that cured
their primary malignancies place them at
increased, lifelong risk for adverse health
conditions (3–5). Late onset cardiac dysfunc-
tion is common, and the attribution of major
cardiac events to childhood exposure to
chest-directed radiotherapy (RT) and anthra-
cycline chemotherapy is now well estab-lished (6,7). The cumulative incidence of congestive
heart failure by 30 years from diagnosis is 12% for
those exposed to both chest-directed RT and anthra-
cycline therapy, and treatment-related cardiac death
is the most common noncancer cause of mortality in
this population (7–9).SEE PAGE 2523This high risk for adult-onset cardiac dysfunction
warrants early detection, when intervention is ex-
pected to be of greatest beneﬁt (10). The Children’s
Oncology Group long-term follow-up guidelines
recommend periodic evaluation by echocardiography
(11). Left ventricular (LV) ejection fraction (LVEF) is
the established parameter for the evaluation of LV
systolic function. However, LVEF by echocardiogra-
phy is only reliable to detect differences of 10% or
more (12,13) and often overestimates the true LVEF in
survivors as measured by cardiac magnetic resonance
imaging, the reference standard for LVEF (14). In
addition, at least 47% of heart failure in the general
population is diastolic in nature, occurring with a
preserved LVEF (15).
More sensitive screening modalities for LV dys-
function are needed. Reduction in LVEF likely occurs
late in the natural history of treatment-related injury,
as it may not be overt until a substantial amount of
cardiac reserve has been exhausted (16). Global longi-
tudinal strain is a well-validated, reproducible
technique for measurement of LV deformation (17).
In noncancer populations, reduced global longi-
tudinal strain is a signiﬁcant, independent predictor of
cardiac mortality and major cardiac events, with
prognostic value superior to that of LVEF (18–20).r. Marwick has received research grants from General Electric (>
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therapy, early reduction in global longitudinal strain
predicts subsequent chemotherapy-related cardiac
dysfunction (21–23). Despite these promising ﬁndings,
myocardial strain for the early detection of cardiac
dysfunction has not been systematically evaluated in a
large population of aging adult survivors of childhood
cancer.
Our objectives were to: 1) determine the preva-
lence of late onset cardiac dysfunction in a large
population of adult, 10-year survivors of childhood
malignancies using state-of-the-art comprehensive
echocardiographic evaluation of cardiac function
(3-dimensional [3D] LVEF, myocardial strain imaging,
and comprehensive diastolic assessment); 2) identify
whether abnormal myocardial strain was associated
with anthracycline and chest-directed RT dose
exposures; and 3) identify strain imaging abnormal-
ities in survivors exposed to cardiotoxic therapy
who subsequently developed traditional cardiovas-
cular risk factors and/or metabolic syndrome, a
population at very high risk for major cardiac
events (8,24,25).
METHODS
PARTICIPANTS. Patients treated for childhood can-
cer at St. Jude Children’s Research Hospital who were
18 years of age or older and 10 or more years from
diagnosis were eligible for SJLIFE (St. Jude Lifetime
Cohort Study). SJLIFE provides lifetime, risk-based
longitudinal follow-up for adult survivors of child-
hood cancer. The current analysis was limited to
participants exposed to anthracycline chemotherapy
and/or chest-directed RT who underwent a SJLIFE
medical assessment, including echocardiography,
because of their prior exposure to cardiotoxic therapy
and reports on the baseline assessment at entry into
the SJLIFE cohort. Participants who completed the
SJLIFE survey only (i.e., no campus visit for direct
assessment) were excluded. Details of eligibility,
recruitment methods, and study design have been
previously published (26). Participation involved the
completion of questionnaires and risk-based medical
screening according to the Long-Term Follow-Up
Guidelines for Survivors of Childhood, Adolescent,$50,000); and equipment support from Siemens and
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2513and Young Adult Cancers (11), developed by the Chil-
dren’s Oncology Group. The Institutional Review
Board at St. Jude Children’s Research Hospital
approved the investigation.
OUTCOME MEASURES. Echocardiograms were ob-
tained using a Vivid 7 machine (n ¼ 1,750 [96%]; GE
Medical Systems, Milwaukee, Wisconsin) or an iE33
(n ¼ 70; Philips Medical Systems, Andover, Massa-
chusetts). Complete systolic function by 3D echocar-
diography with Doppler was performed according
to American Society of Echocardiography (ASE)
guidelines (abnormal, LVEF < 50%) (27). For Vivid 7
studies, speckle tracking–based global longitudinal
peak systolic strain and global circumferential strain
were obtained using 3 apical views with standard,
commercially available software (EchoPAC PC version
10.0; GE Medical Systems).
Abnormal strain was deﬁned as >2 SDs below the
mean using sex-speciﬁc, age-speciﬁc, and vendor-
speciﬁc strain values identiﬁed in a normative
population (28). The largest potential normative
populations, based on a recent meta-analysis of U.S.
data were extremely small (Marwick et al. [29],
Cleveland Clinic: n ¼ 97; Saleh et al. [30], Mayo Clinic:
n ¼ 82; and Narayanan et al. [31], University of Mas-
sachusetts: n ¼ 52). Given the known associations of
age and sex with strain outcomes, as recently dis-
cussed in “Expert Consensus for Multimodality Im-
aging Evaluation of Adult Patients During and After
Cancer Therapy” (16), these small populations would
clearly not allow us to stratify comparisons of these
key variables between our study population and the
normative population. In particular, our study popu-
lation is generally younger than these U.S. cohorts.
Thus, we determined that use of these small cohorts
that do not contain age-speciﬁc, sex-speciﬁc, and
vendor-speciﬁc normative data would be a particular
risk to the validity of the study ﬁndings. Alterna-
tively, the JUSTICE (Japanese Ultrasound Speckle
Tracking of the Left Ventricle) study (28) evaluated a
large population (n ¼ 817) and provided age-speciﬁc
and sex-speciﬁc normative values, which improve
the ability to provide valid comparisons between our
cases and the normative standard. Although this does
raise the possibility that the Japanese and U.S. pop-
ulations may have different strain values on the basis
of race, we were reassured by recent evidence to the
contrary from similar sex-speciﬁc and vendor-speciﬁc
normative values in a European population (32).
Diastolic assessment included peak mitral ﬂow
velocity (E), mitral septal and lateral early diastolic
velocity (e0), their ratios with E (E/e0 ratio), and
left atrial volume (33). Diastolic function was graded
per ASE recommendations for the evaluation ofLV diastolic function, with any grade from 1 to 3
considered abnormal (33). A core echocardiography
laboratory at the Cleveland Clinic centrally evaluated
all echocardiograms.
To estimate the interobserver variability, the lead
cardiologist for this study from the Cleveland Clinic
echocardiography core lab (J.C.P., who read 625 of
the 1,807 evaluable studies) reviewed a sample of
echocardiograms read by each of the other cardiolo-
gists. We randomly selected 10 studies from each
of the 6 additional reviewers (60 total studies). Se-
lection was stratiﬁed on LVEF <50% versus $50% to
ensure the inclusion of a sufﬁcient number of both
normal and abnormal echocardiograms in the review.
Across our major echocardiographic outcomes, over-
all agreement (normal vs. abnormal) was as follows:
for LVEF, 76% agreement; for global longitudinal
strain, 76% agreement; for circumferential strain,
36% agreement; for left atrial volume, 95% agree-
ment; and for lateral e0 60% agreement.
DEMOGRAPHIC AND EXPOSURE VARIABLES. The
cumulative anthracycline dose was abstracted from
the medical record along with demographic charac-
teristics. As described by Stovall et al. (34), the primary
RT record and tissue-equivalent phantoms were used
to estimate the mean radiation dose to the heart,
regardless of primary tumor site or target volume.
Additional covariates included metabolic syndrome
and its components. Metabolic syndrome was deﬁned
using the third report of the National Cholesterol Ed-
ucation Program Adult Treatment Panel (35). Patients
with 3 or more of the following were classiﬁed as hav-
ing metabolic syndrome: 1) abdominal obesity (waist
circumference>102 cm inmen and>88 cm in women);
2) triglycerides $150 mg/dl or treatment for elevated
triglycerides; 3) high-density lipoprotein cholesterol
<40 mg/dl in men and <50 mg/dl in women; 4) hy-
pertension (systolic blood pressure $130 mm Hg or
diastolic blood pressure $85 mm Hg) or treatment
for hypertension; and 5) fasting plasma glucose
$100 mg/dl or medical therapy for diabetes.
Abdominal circumference at the narrowest point
between the xiphoid process and the navel was
determined with a Gullick tape measure (36), with the
measurement repeated twice and recorded to the
nearest 0.1 cm. The highest abdominal circumference
measurement was used for analysis. Resting blood
pressure was taken after a 5-min rest period, with
the participant seated with both feet on the ﬂoor.
Duplicate readings were taken to ensure accuracy;
participants rested for 1 min between measurements.
The lowest of 3 blood pressure measurements was
used for analysis.
TABLE 1 Demographic and Treatment Characteristics of Adult Survivors of Childhood Cancer
Eligible
(n ¼ 3,029)
Nonparticipants
(n ¼ 1,209)
Participants
(n ¼ 1,820)
Anthracycline Alone
(n ¼ 1,050)
Chest-Directed
RT Alone
(n ¼ 306)
Anthracycline þ
Chest-Directed RT
(n ¼ 464)
n %* n %* n %* n %* n %* n %*
Race/ethnicity
Non-Hispanic white 2,517 83.8 965 81.2 1,552 85.5 905 86.4 260 85.0 387 83.8
Non-Hispanic black 415 13.8 193 16.2 222 12.2 116 11.1 40 13.1 66 14.3
Non-Hispanic other 41 1.4 18 1.5 23 1.3 12 1.2 6 2.0 5 1.1
Hispanic 31 1.0 13 1.1 18 1.0 14 1.3 0 0.0 4 0.9
Sex
Male 1,684 55.6 738 61.0 946 52.0 548 52.2 164 53.6 234 50.4
Female 1,345 44.4 471 39.0 874 48.0 502 47.8 142 46.4 230 49.6
Age at diagnosis, yrs
0–4 1,023 33.8 404 33.4 619 34.0 416 39.6 69 22.6 134 28.9
5–9 718 23.7 296 24.5 422 23.2 246 23.4 79 25.8 97 20.9
10–14 731 24.1 286 23.7 445 24.5 242 23.1 95 31.1 108 23.3
15–19 530 17.5 210 17.4 320 17.6 138 13.1 61 19.9 121 26.1
>19 27 0.9 13 1.1 14 0.8 8 0.8 2 0.7 4 0.9
Time since diagnosis, yrs
10–20 1,027 34.1 366 30.3 661 36.3 392 37.5 80 26.3 189 41.3
21–30 1,228 40.7 498 41.2 730 40.1 468 44.8 87 28.6 175 38.2
31–40 643 21.3 280 23.2 363 19.9 179 17.1 101 33.2 83 18.1
41–50 118 3.9 65 5.4 53 2.9 6 0.6 36 11.8 11 2.4
Current age, yrs
18–20 139 4.6 51 4.2 88 4.8 69 6.6 3 1.0 16 3.5
21–30 1,193 39.6 430 35.6 763 41.9 506 48.4 88 29.0 169 36.9
31–40 1,112 36.9 462 38.2 650 35.7 356 34.1 84 27.6 210 45.9
41–50 484 16.1 217 18.0 267 14.7 107 10.2 103 33.9 57 12.5
>50 88 2.9 49 4.1 39 2.1 7 0.7 26 8.6 6 1.3
Primary cancer diagnosis
Leukemia 1,246 41.1 479 39.6 767 42.1 601 57.2 54 17.7 112 24.1
Acute lymphoblastic leukemia 1,053 34.8 384 31.8 669 36.8 550 52.4 31 10.1 88 19.0
Acute myeloid leukemia 146 4.8 72 6 74 4.1 51 4.9 1 0.3 22 4.7
Other leukemia 47 1.6 23 1.9 24 1.3 0 0.0 22 7.2 2 0.4
Lymphoma 799 26.4 332 27.5 467 25.7 136 13.0 121 39.5 210 45.3
Non-Hodgkin lymphoma 307 10.1 151 12.5 156 8.6 120 11.4 11 3.6 25 5.4
Hodgkin lymphoma 492 16.2 181 15 311 17.1 16 1.5 110 36.0 185 39.9
CNS tumor 140 4.6 62 5.1 78 4.3 2 0.2 76 24.8 0 0.0
Bone tumor 261 8.6 88 7.3 173 9.5 150 14.3 0 0.0 23 5.0
Ewing sarcoma 119 3.9 38 3.1 81 4.5 60 5.7 0 0.0 21 4.5
Osteosarcoma 142 4.7 50 4.1 92 5.1 90 8.6 0 0.0 2 0.4
Soft tissue sarcoma 143 4.7 59 4.9 84 4.6 60 5.7 5 1.6 19 4.1
Rhabdomyosarcoma 97 3.2 43 3.6 54 3 42 4.0 3 1.0 9 1.9
Nonrhabdo sarcoma 46 1.5 16 1.3 30 1.6 18 1.7 2 0.7 10 2.2
Other malignancies
Germ cell tumor 20 0.7 11 0.9 9 0.5 0 0.0 9 2.9 0 0.0
Melanoma 3 0.1 2 0.2 1 0.1 0 0.0 1 0.3 0 0.0
Neuroblastoma 142 4.7 57 4.7 85 4.7 60 5.7 13 4.3 12 2.6
Retinoblastoma 16 0.5 11 0.9 5 0.3 5 0.5 0 0.0 0 0.0
Wilms tumor 230 7.6 97 8 133 7.3 26 2.5 20 6.5 87 18.8
Carcinoma 6 0.2 3 0.2 3 0.2 1 0.1 2 0.7 0 0.0
Other 23 0.8 8 0.7 15 0.8 9 0.9 5 1.6 1 0.2
Continued on the next page
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2514Blood samples were collected after an over-
night fast. Triglycerides and high-density lipoprotein
were measured using an enzymatic spectrophoto-
metric assay (Roche Diagnostics, Indianapolis,Indiana). Glucose was measured using an enzymatic
spectrophotometric assay using hexokinase coupled
with glucose-6-phosphate dehydrogenase (Roche Di-
agnostics). All samples were analyzed using the
TABLE 1 Continued
Eligible
(n ¼ 3,029)
Nonparticipants
(n ¼ 1,209)
Participants
(n ¼ 1,820)
Anthracycline Alone
(n ¼ 1,050)
Chest-Directed
RT Alone
(n ¼ 306)
Anthracycline þ
Chest-Directed RT
(n ¼ 464)
n %* n %* n %* n %* n %* n %*
Anthracycline cumulative dose, mg/m2
0 510 16.9 204 17.1 306 16.9 0 0.0 306 100.0 0 0.0
1–100 784 26.0 296 24.6 488 26.9 419 40.0 0 0.0 69 15.0
101–200 882 29.2 364 30.3 518 28.6 292 27.9 0 0.0 226 49.0
201–300 336 11.1 141 11.7 195 10.8 105 10.0 0 0.0 90 19.5
301–400 332 11.0 107 8.9 225 12.4 163 15.6 0 0.0 62 13.5
401–500 100 3.3 41 3.4 59 3.3 51 4.9 0 0.0 8 1.7
501–600 23 0.8 5 0.4 18 1.0 13 1.2 0 0.0 5 1.1
>600 48 1.6 43 3.6 5 0.3 4 0.4 0 0.0 1 0.2
Chest-directed RT, Gy
0 1,765 60.5 715 62.1 1,050 59.4 1,050 100.0 0 0.0 0 0.0
1–19.9 653 22.4 250 21.7 403 22.8 0 0.0 131 45.0 272 63.7
20–29.9 330 11.3 121 10.5 209 11.8 0 0.0 72 24.7 137 32.1
$30 172 5.9 66 5.7 106 6.0 0 0.0 88 30.2 18 4.2
Metabolic syndrome
Yes — — — — 509 28.6 280 27.2 99 33.5 130 28.8
No — — — — 1,269 71.4 750 72.8 197 66.6 322 71.2
Components of metabolic syndrome
Abdominal obesity
Yes — — — — 538 30.4 355 34.5 69 23.7 114 25.4
No — — — — 1,232 69.6 675 65.5 222 76.3 335 74.6
Elevated triglycerides
Yes — — — — 470 26.0 234 22.4 98 32.2 138 30.0
No — — — — 1,338 74.0 810 77.6 206 67.8 322 70.0
Low HDL cholesterol
Yes — — — — 665 36.8 379 36.3 113 37.2 173 37.6
No — — — — 1,143 63.2 665 63.7 191 62.8 287 62.4
Hypertension
Yes — — — — 816 45.2 436 41.8 160 53.2 220 47.8
No — — — — 989 54.8 608 58.2 141 46.8 240 52.2
Fasting glucose $100 mg/dl
Yes — — — — 577 31.9 295 28.2 125 41.1 157 34.1
No — — — — 1,233 68.1 750 71.8 179 58.9 304 65.9
Previously diagnosed
with cardiomyopathy
— — — — 47 2.6 19 1.8 10 3.3 18 3.9
Previously diagnosed with
cardiomyopathy and
on medications at the
time of evaluation
— — — — 23 1.3 7 0.7 6 2.0 10 2.2
*Percents are provided for the total number of participants for whom data were available for a given characteristic.
CNS ¼ central nervous system; HDL ¼ high-density lipoprotein; RT ¼ radiotherapy.
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2515Roche Modular P chemistry analyzer. Exercise ca-
pacity was determined by a 6-min walk performed
indoors, according to the American Thoracic Society
guidelines (abnormal, <490 m) (37,38). Quality of
life was measured using the physical and mental
component summaries of the SF-36 (39).
STATISTICAL METHODS. Descriptive statistics were
used to characterize the eligible population and study
participants. The prevalence of cardiac abnormalitieswas estimated for the entire cohort of 10-year survi-
vors and by treatment exposure (anthracycline only,
chest-directed RT only, and anthracycline and chest-
directed RT combined). Associations between treat-
ment characteristics and cardiac abnormalities were
investigated using Poisson regression models with
robust error variances. A similar approach was used
to determine whether metabolic syndrome and its
components were associated with abnormal cardiac
function. These models were adjusted for current
FIGURE 1 CONSORT Diagram of SJLIFE Population Eligible for
Echocardiographic Evaluation
Completed Echocardiography
Assessment
(N=1,820)
Evaluable for Analysis
(N=1,807)
Eligible for SJLIFE Cohort
(N=4,436)
Passive Non-Participants (N=392)
Campus Visit Pending (N=296)
Refused (N=260)
Completed Survey Only (N=169)
Lost to Follow-Up (N=92)
Not exposed to Chest RT or
Anthracycline Chemotherapy
(N=1,407)
Echo Not Evaluable for Analysis
(N=13)
Exposed to Chest RT and/or
Anthracycline Chemotherapy
(N=3,029)
CONSORT ¼ Consolidated Standards of Reporting Trials; RT ¼ radiotherapy; SJLIFE ¼ St.
Jude Lifetime Cohort Study.
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2516age, age at diagnosis, race/ethnicity, chest RT and
anthracycline exposure, and the rate ratios (RRs) and
95% conﬁdence intervals (CIs). Frequencies and per-
cents of all combinations of abnormal echocardio-
graphic results were summarized, and 6-min walk
distances were compared with the in the group with
normal echocardiographic results using 2-sample
Student t tests. Associations between cardiac dys-
function and impaired quality of life (deﬁned as
impaired physical and mental quality of life on the
SF-36) were assessed by Poisson regression with
robust error variance and adjusted for sex, education,
marital status, annual household income, employ-
ment status, and treatment with cranial RT. All ana-
lyses were performed in SAS version 9.3 (SAS Institute
Inc., Cary, North Carolina).
RESULTS
Of the 4,436 survivors eligible for SJLIFE, 3,029 were
exposed to cardiotoxic therapy and eligible for
echocardiography (Figure 1). At the time of this
analysis, 1,820 (60% of those eligible) had completedSJLFE medical assessments, including echocardiog-
raphy. Thirteen echocardiographic studies were of
insufﬁcient quality for analysis. Demographic and
treatment characteristics of survivors included in
this analysis and potentially eligible nonparticipants
are summarized in Table 1. Participants were more
likely to be female but were similar on other de-
mographic and treatment-related characteristics.
The median time from primary cancer diagnosis was
22.6 years (range: 10.4 to 48.3 years); the median age
at evaluation was 31 years (range: 18 to 65 years).
Forty-seven survivors had been previously diag-
nosed with cardiomyopathy, 23 of whom were
on medications for heart failure at the time of
evaluation.
Only 5.8% of the population had 3D LVEFs <50%.
However, systolic dysfunction detected by global
longitudinal (31.8%) and global circumferential
(23.1%) strain and by diastolic dysfunction (ASE
grades 1 to 3; 11%) was more prevalent (Central
Illustration, Online Table 1) than an abnormal LVEF.
Among survivors with preserved 3D LVEFs ($50%),
comprehensive echocardiography identiﬁed signiﬁ-
cant systolic (28%; global longitudinal strain) and
diastolic (8.7%; ASE grades 1 to 3) dysfunction. Thus,
when both longitudinal strain and ASE grade 1
to 3 diastolic function were considered, one-third
(32.1%) of survivors with normal 3D LVEFs had car-
diac dysfunction. Notably, among survivors exposed
to chest RT only, 22.4% had evidence of diastolic
dysfunction.
Abnormal 3D LVEF was associated with chest-
directed RT at 20 to 29.9 Gy (RR: 1.86; 95% CI: 1.00
to 3.45) and $30 Gy (RR: 7.99; 95% CI: 3.88 to
16.48) (Table 2) and cumulative anthracycline dose
>100 mg/m2. Global longitudinal strain was as-
sociated with any dose exposure to chest-directed
RT at 1 to 19.9 Gy (rate ratio: 1.38; 95% CI: 1.14 to
1.66), 20 to 29.9 Gy (RR: 1.65; 95% CI: 1.31 to 2.08) and
>30 Gy (RR: 2.39; 95% CI: 1.79 to 3.18) and anthracy-
cline dose >300 mg/m2. Diastolic dysfunction was
associated with chest-directed RT but not with
cumulative dose of anthracycline.
Survivors with metabolic syndrome were almost
twice as likely to have abnormal global longitudinal
strain (RR: 1.94; 95% CI: 1.66 to 2.28) and abnormal
diastolic function (RR: 1.68; 95% CI: 1.39 to 2.03)
but did not have a higher risk for abnormal 3D LVEF
(RR: 1.07; 95% CI: 0.74 to 1.53). Each individual
component of metabolic syndrome was associated
with an increased risk for abnormal global longitudi-
nal strain and diastolic dysfunction (Table 3).
Reduced exercise capacity (<490 m, 6-min
walk) was identiﬁed in 17.6% of participants
CENTRAL ILLUSTRATION Prevalence of Cardiac Dysfunction and Reduced Exercise Capacity in Adult, 10-Year Survivors of
Childhood Cancer
Armstrong, G.T. et al. J Am Coll Cardiol. 2015; 65(23):2511–22.
 Lateral e'
EF ¼ ejection fraction; RT ¼ radiotherapy; 3D ¼ 3-dimensional.
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2517(Central Illustration). Survivors with global longitudi-
nal strain as the only abnormal ﬁnding on echocar-
diography had a lower mean 6-min walk distance
compared with survivors with normal echocardio-
graphic results (560 vs. 590 m; p ¼ 0.0002; Online
Table 2). However, on multivariate analyses adjust-
ing for pulmonary function, muscle strength, height,
and weight, no independent association between
echocardiographic outcomes and reduced exercise
capacity was identiﬁed.
Abnormal longitudinal strain (RR: 1.71; 95% CI:
1.33 to 2.19), LVEF (RR: 1.92; 95% CI: 1.33 to 2.76),
and diastolic function (grades 1 to 3; RR: 1.83; 95% CI:
1.36 to 2.45) were associated with reduced quality of
life on the physical component summary scale, but
only abnormal LVEF (RR: 1.53; 95% CI: 1.02 to 2.29)
and abnormal atrial volume (RR: 1.37; 95% CI: 1.01
to 1.86) were associated with the mental component
summary scale of the SF-36 (Online Table 3).
DISCUSSION
Systematic, protocol-driven echocardiographic as-
sessment of a large population of adult survivors of
childhood cancer has been difﬁcult to achieve as this
population has transitioned from academic pediatriccenters to adult care, largely provided in a community
setting (40). However, with more than 1,800 partici-
pants, we provide the largest study to date using
modern echocardiographic techniques (3D LVEF [14];
myocardial strain; and uniform, ASE guideline-driven
grading of diastolic function) for the comprehensive
assessment of cardiac function in aging adult sur-
vivors of childhood cancer exposed to cardiotoxic
therapy (41–43). Only 5.8% had 3D LVEFs <50%.
However, by applying comprehensive echocardio-
graphic assessment, we identiﬁed evidence of un-
derlying systolic and/or diastolic cardiac dysfunction
in one-third of survivors with normal 3D LVEFs.
DIASTOLIC FUNCTION. It is known that chest-
directed RT results in microvascular damage with
subsequent myocardial interstitial ﬁbrosis, leading to
a noncompliant ventricle with resulting diastolic
dysfunction, often with preserved LVEF (44). Tradi-
tionally, diastolic dysfunction has been difﬁcult to
quantify in survivors of childhood cancer (45,46),
with more accurate assessment occurring in adults
diagnosed with Hodgkin lymphoma (47). Given
the large size of our population, evaluation of
the independent effect of chest-directed RT, with-
out the confounding inﬂuence of anthracyclines
was possible. Our use of the ASE consensus-based
TABLE 2 Multivariate Associations Between Treatment Characteristics and Systolic and Diastolic Dysfunction in Adult Survivors of Childhood Cancer
3D LVEF < 50%
Abnormal Global
Longitudinal Strain
Abnormal Global
Circumferential Strain
Diastolic
Grade 1–3
Abnormal
Lateral e0
Abnormal Left
Atrial Volume
RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Race/ethnicity
Other 1.53 0.93–2.52 1.22 1.03–1.46 0.84 0.64–1.09 1.24 0.86–1.78 1.32 0.89–1.96 2.03 1.41–2.93
Non-Hispanic white 1.00 1.00 1.00 1.00 1.00
Sex
Female 0.54 0.36–0.83 1.55 1.34–1.79 1.01 0.84–1.21 1.15 0.88–1.51 0.98 0.73–1.32 0.60 0.43–0.83
Male 1.00 1.00 1.00 1.00 1.00 1.00
Age at diagnosis, yrs
0–4 0.66 0.35–1.27 1.02 0.82–1.27 1.24 0.92–1.67 0.85 0.56–1.29 0.91 0.58–1.44 1.26 0.79–2.01
5–9 0.67 0.36–1.25 0.92 0.74–1.15 1.01 0.74–1.38 0.81 0.53–1.22 0.80 0.50–1.26 1.23 0.74–2.05
10–14 1.02 0.59–1.76 1.02 0.83–1.24 1.11 0.84–1.48 0.87 0.61–1.23 0.77 0.50–1.17 1.18 0.74–1.86
$15 1.00 1.00 1.00 1.00 1.00 1.00
Current age, yrs
31–40 1.38 0.81–2.35 1.25 1.05–1.48 0.85 0.69–1.06 2.43 1.59–3.71 1.96 1.31–2.93 2.40 1.67–3.45
>40 0.98 0.52–1.84 1.49 1.20–1.85 0.98 0.73–1.33 4.74 2.90–7.75 1.52 0.90–2.54 3.59 2.25–5.73
18–30 1.00 1.00 1.00 1.00 1.00 1.00
Anthracycline cumulative
dose, mg/m2
1–100 1.74 0.66–4.61 1.38 1.05–1.82 0.99 0.66–1.48 0.75 0.43–1.30 0.62 0.29–1.32 2.07 0.95–4.51
101–200 2.80 1.24–6.31 1.16 0.89–1.50 1.24 0.86–1.79 0.80 0.51–1.25 1.13 0.65–1.97 1.82 0.85–3.91
201–300 3.80 1.59–9.10 1.06 0.78–1.45 1.36 0.90–2.04 0.76 0.42–1.37 1.77 0.99–3.15 1.34 0.55–3.25
301–400 4.76 2.16–10.50 1.72 1.31–2.26 1.61 1.08–2.40 1.00 0.59–1.69 1.53 0.84 2.81 1.72 0.73–4.05
>400 7.71 3.04–19.57 1.73 1.19–2.50 1.34 0.78–2.31 1.33 0.72–2.45 2.05 0.99–4.24 0.95 0.30–2.99
None 1.00 1.00 1.00 1.00 1.00 1.00
Chest RT cumulative dose (Gy)
1–19.9 1.24 0.70–2.22 1.38 1.14–1.66 0.86 0.66–1.11 1.47 0.99–2.20 1.09 0.69–1.72 0.47 0.29–0.78
20–29.9 1.86 1.00–3.45 1.65 1.31–2.08 1.14 0.83–1.57 2.03 1.30–3.17 2.01 1.27–3.21 1.10 0.65–1.87
$30 7.99 3.88–16.48 2.39 1.79–3.18 1.64 1.05–2.56 2.44 1.44–4.14 4.03 2.22–7.32 0.63 0.21–1.89
None 1.00 1.00 1.00 1.00 1.00 1.00
Values in bold are statistically signiﬁcant.
CI ¼ conﬁdence interval; LVEF ¼ left ventricular ejection fraction; RR ¼ rate ratio; RT ¼ radiotherapy; 3D ¼ 3-dimensional.
Armstrong et al. J A C C V O L . 6 5 , N O . 2 3 , 2 0 1 5
Cardiac Dysfunction After Childhood Cancer J U N E 1 6 , 2 0 1 5 : 2 5 1 1 – 2 2
2518diastolic assessment found that 22% of survivors
exposed to RT alone had evidence of diastolic
dysfunction. These ﬁndings are driven by the large
number of survivors of Hodgkin lymphoma treated
with high doses of chest-directed RT before the era in
which combined-modality therapy with anthracy-
clines and low-dose, involved-ﬁeld chest RT was
introduced. Many of these survivors, who have a well-
documented increased risk for major cardiac events,
are now entering the ﬁfth decade of life (6,8). Thus,
our ﬁndings underscore that screening evaluations
of these survivors cannot be limited to traditional
assessment of LV systolic function but should also
include comprehensive diastolic assessment.
SYSTOLIC FUNCTION. Strain imaging has emerged as
a powerful tool to quantify myocardial mechanics,
including both longitudinal shortening and circum-
ferential torsion (17). Although LVEF is the most
widely used measure of systolic dysfunction, it has a
number of limitations, including the use of geome-
tric assumptions (2-dimensional LVEF) of ventricularshape, load dependency, and poor reproducibility
and interobserver variability (20). Myocardial strain is
a semiautomated tool to assess multidimensional
myocardial deformation that is more reproducible
and not reliant on geometric assumptions (17). In the
general population, the association of LVEF with
poor outcome is strongest in moderately to severely
impaired ventricles (48). Thus, LVEF may not be ideal
for screening asymptomatic survivors. Furthermore,
in a recent meta-analysis that included almost 6,000
patients with a diverse array of underlying cardiac
insults (congestive heart failure, acute myocardial
infarction, valvular disease), global longitudinal
strain had superior prognostic value compared with
LVEF for predicting both overall mortality and major
cardiac events (20). In that meta-analysis, a 1-SD
change in global longitudinal strain was associated
with a 1.62-fold (95% CI: 1.13 to 2.33) greater re-
duction in mortality than a comparable change in
LVEF. Given that evidence from the general non-
cancer population indicates that abnormal global
TABLE 3 Association Between Metabolic Syndrome and Systolic and Diastolic Echocardiographic Abnormalities in Adult Survivors of
Childhood Cancer*
3D LVEF < 50%
Abnormal Global
Longitudinal Strain
Abnormal Global
Circumferential Strain
Diastolic
Grade 1–3
Abnormal
Lateral e0
Abnormal Left Atrial
Volume
RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI RR 95% CI
Metabolic syndrome
Yes 1.07 0.74–1.53 1.94 1.66–2.28 1.02 0.84–1.24 1.68 1.39–2.03 1.65 1.35–2.02 1.41 1.14–1.74
No 1.00 1.00 1.00 1.00 1.00 1.00
Abdominal obesity
Yes 1.34 0.99–1.82 1.73 1.48–2.01 1.10 0.92–1.32 1.69 1.39–2.06 1.49 1.23–1.82 1.83 1.53–2.19
No 1.00 1.00 1.00 1.00 1.00 1.00
Triglycerides $ 150 mg/dl
Yes 1.01 0.70–1.44 1.65 1.40–1.95 1.01 0.82–1.23 1.44 1.17–1.78 1.35 1.07–1.70 1.03 0.79–1.33
No 1.00 1.00 1.00 1.00 1.00 1.00
Low HDL cholesterol
Yes 1.01 0.74–1.38 1.40 1.23–1.59 0.92 0.78–1.08 1.36 1.14–1.62 1.20 0.97–1.47 1.20 0.98–1.47
No 1.00 1.00 1.00 1.00 1.00 1.00
Hypertension
Yes 1.44 1.22–1.70 1.48 1.33–1.65 1.04 0.92–1.18 1.39 1.22–1.58 1.34 1.17–1.55 1.30 1.13–1.49
No 1.00 1.00 1 1.00 1.00 1.00
Fasting glucose $100 mg/dl
Yes 1.02 0.75–1.39 1.37 1.19–1.59 1.06 0.89–1.25 1.42 1.18–1.70 1.47 1.22–1.77 1.00 0.81–1.25
No 1.00 1.00 1.00 1.00 1.00 1.00
Values in bold are statistically signiﬁcant. *Adjusted for current age, age at diagnosis, race/ethnicity, sex, chest RT, and anthracycline exposure.
Abbreviations as in Tables 1 and 2.
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2519longitudinal strain is a valid predictor of poor
outcome, our ﬁnding that 28% of survivors with
normal 3D LVEFs have abnormal global longitudinal
strain may identify a subset of survivors at high
risk for clinical heart failure. It will be essential
that future studies provide longitudinal follow-up
of survivors evaluated with comprehensive echocar-
diographic imaging to determine whether (as in
the general population) global longitudinal strain
improves the prediction of major cardiac events.
The present study takes important steps in vali-
dating global longitudinal strain as a clinically rele-
vant measure in survivors. First, we established
that global longitudinal strain, like LVEF, measures
treatment-related injury in this population. On
the strength of detailed abstraction of cumula-
tive dose exposure of anthracyclines and tissue-
speciﬁc radiation dosimetry, we demonstrated that
abnormal global longitudinal strain, but not global
circumferential stain, was associated with increasing
doses of both anthracyclines and chest-directed RT.
Dose-response relationships between exposure and
major cardiac events are well established in this
population (6,10); thus, if strain is to be a meaningful
early measure of cardiac injury, demonstrating a
dose-response relationship is essential. Furthermore,
studies in adult cancer populations have demon-
strated changes in global longitudinal strain duringthe administration of anthracyclines (49). In these
trials, early changes in global longitudinal strain
precede and predict eventual reduction in LVEF and
subsequent clinical heart failure (22). These ﬁndings
have resulted in an expert consensus statement
from the ASE that recommends strain in the assess-
ment of adult patients during and after cancer ther-
apy (16). In the present study, abnormal global
circumferential strain, though prevalent, showed
inconsistent associations with increased anthracy-
cline or chest-directed RT exposure. This may be
because the subendocardial region, which governs
longitudinal LV mechanics, is generally the region
most sensitive to myocardial injury (50). These ﬁnd-
ings should direct clinicians toward the preferential
use of global longitudinal strain over circumferential
strain in screening of this population.
It is now established that among aging survivors
who received cardiotoxic therapies, the acquisition of
traditional cardiovascular risk factors and metabolic
syndrome potentiates risk for major cardiac events
(8,24). More sensitive echocardiographic measures of
cardiac injury would be expected to demonstrate
higher rates of abnormal function in a population
with metabolic syndrome. We identiﬁed higher rates
of abnormal global longitudinal strain, but not
3D LVEF, in a subset of the population with meta-
bolic syndrome. This strong association between
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Survivors of chest-directed RT and anthracycline
chemotherapy for cancer in childhood are at risk
for cardiac morbidity and mortality as adults.
TRANSITIONAL OUTLOOK: Additional work is
needed to characterize the temporal evolution of
structural and functional cardiac abnormalities during
adulthood that arise as a consequence of therapy for
cancer during childhood and predict adverse cardiac
events.
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2520therapeutic dose exposure and increased rates of
abnormal ﬁndings in a high-risk subset of the popu-
lation with metabolic syndrome suggests that global
longitudinal strain may be a valid measure for
detecting myocardial injury in adult survivors of
childhood cancer. However, baseline assessment
before treatment and serial, longitudinal evaluation
with strain in a large population of aging survivors are
needed before this can be concluded.
STUDY LIMITATIONS. Eight previous studies have
reported strain evaluation among a total of 366
long-term survivors of childhood cancer (largest
study population, n ¼ 111) (49,51) and identiﬁed
between 6% and 30% of the population to have
abnormal longitudinal strain. We present the most
systematic assessment to date, including a study
population of sufﬁcient size for a robust multivariate
analysis to evaluate confounding variables contrib-
uting to cardiac outcomes. Nonetheless, limitations
should be considered. The cross-sectional nature
of this analysis precludes deﬁnitive assessment of the
predictive nature of global longitudinal strain, or
any echocardiographic parameter, for major cardiac
events, including congestive heart failure, cardiac
hospitalization, and cardiac mortality. However,
longitudinal follow-up of the SJLIFE cohort will
allow future assessments as survivors age. Although
the quality of echocardiography is inherently oper-
ator dependent, this protocol-driven systematic
assessment should limit the imprecision inherent in
previous studies that have reported on echocardiog-
raphy by retrospective review. Furthermore, our use
of 3D LVEF eliminates assumptions regarding ven-
tricular size inherent in 2-dimensional LVEF esti-
mates, providing the most valid assessment of LVEF
to date (14). It is important to note that independent
associations between echocardiographic abnormal-
ities and reduced functional performance on the
6-min walk test were not identiﬁed on multivariate
analysis. This may be a result of 6-min walk dis-
tance’s being a poor surrogate for performance in this
population. Thus, future studies will include maximal
treadmill testing to assess functional performance.
Additionally, calculation of mean RT dose to the
heart, although providing organ-speciﬁc dosimetry,
may not fully describe the differential dose receivedacross the heart. Finally, current circumferential
strain estimations may be unreliable, and future ef-
forts should focus on improvement in reliability and
validity.
CONCLUSIONS
These ﬁndings suggest that traditional echocardio-
graphic evaluation of cardiac function in adult sur-
vivors of childhood cancer that focuses on LVEF as
the primary measure of function may be inadequate.
Evaluations that incorporate global longitudinal
strain and ASE grading of diastolic function de-
monstrate evidence of cardiac dysfunction in 1 in 3
survivors with normal LVEFs. Long-term follow-up
is needed to determine the predictive nature of
these echocardiographic ﬁndings for major cardiac
events.
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